v3.26.3
Stock-Based Compensation - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 22, 2026
USD ($)
HOLDER
shares
Jan. 01, 2026
shares
Aug. 31, 2024
$ / shares
shares
Mar. 31, 2024
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Options to purchase shares of common stock         5,945,000   5,945,000   4,234,000 3,818,000
Increamental non cash stock based compensation | $                 $ 900  
Aggregate shares of common stock         33,000   33,000   0 0
Unrecognized compensation cost related to outstanding time-based vesting | $         $ 0   $ 0   $ 9,200  
Unrecognized compensation cost expected to be recognized over a weighted-average period                 2 years 2 months 12 days  
Weighted-average grant date per share fair value of options granted | $ / shares         $ 1.12 $ 0.89 $ 1.05 $ 1.89 $ 1.88 $ 7.19
Common stock reserved for future issuance         9,162,000   9,162,000   7,885,000 6,653,000
Stock-based compensation | $         $ 3,222 $ 1,693 $ 4,593 $ 3,490 $ 6,125 $ 7,516
Shares issued under ESPP         35,000 86,000        
Expected term         5 years 3 months 18 days 5 years 10 months 24 days 5 years 10 months 24 days 5 years 10 months 24 days 5 years 10 months 24 days 6 years
Expected volatility         105.00% 105.00% 107.00% 105.00% 105.20% 90.80%
Risk-free interest rate         4.20% 4.00% 4.00% 4.40% 4.40% 3.90%
Total intrinsic value of stock options exercised | $             $ 14,000 $ 0    
Options to Purchase Common Stock | Serapha Bio Inc [Member] | Merger Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation | $             2,000      
Plan modification, number of accelerated vesting options to purchase shares of common shares 5,945,008                  
Plan modification, number of option holders affected | HOLDER 48                  
Incremental compensation cost resulting from extension of exercise period and acceleration of premium end date | $ $ 400                  
Expected term 9 months 18 days                  
Expected volatility 98.80%                  
Risk-free interest rate 4.00%                  
Expected dividend yield 0.00%                  
ESPP                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Unrecognized compensation cost related to outstanding time-based vesting | $         $ 300   $ 300   $ 600  
Unrecognized compensation cost expected to be recognized over a weighted-average period                 1 year 3 months 18 days  
Offering period       24 months            
Purchase period       6 months            
Percentage of fair market value of common stock purchase price       85.00%            
Common stock reserved for future issuance         492,641   492,641      
Stock-based compensation | $                 $ 400 $ 500
Shares issued under ESPP             34,610 85,568 107,208 44,532
Percentage of outstanding common stock maximum       1.00%            
ESPP | Subsequent Event                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Number of shares authorized for issuance   678,991                
Aggregate number of shares issued increased   224,072                
Repriced Options                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Options to purchase shares of common stock         2,208,476   2,208,476      
Exercise price | $ / shares     $ 3.56              
Increamental non cash stock based compensation | $                 $ 200  
Increamental non cash stock based compensation expense related unvested repriced options | $                 700  
Repriced Options | Maximum                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Options to purchase shares of common stock     3,484,346              
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation | $         $ 2,296 $ 1,051 $ 3,276 $ 2,133 3,989 $ 4,466
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Options to Purchase Common Stock | Serapha Bio Inc [Member] | Merger Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation | $         1,500   1,500      
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Repriced Options                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Increamental non cash stock based compensation expense related unvested repriced options | $                 200 100
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation | $         $ 926 $ 642 1,317 $ 1,357 $ 2,136 $ 3,050
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Options to Purchase Common Stock | Serapha Bio Inc [Member] | Merger Agreement [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock-based compensation | $             $ 500      
2024 Incentive Award Plan                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Term of the plan       10 years            
Percentage of excise price       100.00%            
Number of shares authorized for issuance         5,068,078   5,068,078   3,947,716  
Number of shares remained available for grant         2,724,148   2,724,148   3,347,667  
Aggregate number of shares issued increased   1,120,362                
Percentage of outstanding common stock maximum       5.00%            
2024 Incentive Award Plan | Subsequent Event                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Number of shares authorized for issuance   5,068,078                
Aggregate number of shares issued increased   1,120,362                
2024 Incentive Award Plan | Options to Purchase Common Stock | Minimum                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Vesting period       36 months            
2024 Incentive Plan                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Term of the plan       10 years            
2024 Incentive Plan | Options to Purchase Common Stock | Maximum                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Vesting period       48 months